Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new approach to immunosuppression at the complement level-hypothesis.

S S Asghar1, R A Asghar

  • 1Department of Dermatology, Academic Medical Center, University of Amsterdam, The Netherlands.

Medical Hypotheses
|June 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of C1r, C1s and generation of C1s by amidino compounds.

Biochimica et biophysica acta·2009
Same author

Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo.

The British journal of dermatology·2002
Same author

Defensins and complement systems from the perspective of skin immunity and autoimmunity.

Clinics in dermatology·2001
Same author

Therapeutic inhibition of the complement system. Y2K update.

Frontiers in bioscience : a journal and virtual library·2000
Same author

Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines.

The Journal of investigative dermatology·2000
Same author

Transforming growth factor-beta isoforms regulate the surface expression of membrane cofactor protein (CD46) and CD59 on human keratinocytes [corrected].

European journal of immunology·1999

This study proposes a novel treatment for immunological diseases involving the classical pathway (CP) of complement. Inhibiting the active site of Cls with F(ab)2 fragments may suppress disease activity by preventing complement-mediated tissue destruction.

Area of Science:

  • Immunology
  • Complement System Biology

Background:

  • Certain immunological diseases involve the classical pathway (CP) of complement in their pathogenesis.
  • CP activation contributes significantly to disease activity in specific clinical contexts.

Purpose of the Study:

  • To present a conceptual hypothesis for treating immunological diseases.
  • To propose the use of F(ab)2 fragments of monoclonal antibodies targeting the active site of Cls for disease suppression.

Main Methods:

  • Administration of F(ab)2 fragments specific for the active site of human Cls.
  • Hypothesized mechanism involves targeted inhibition without affecting total Cls or CP levels.
  • Proposed testing in experimental models using rat or mouse monoclonal antibodies against rat Cls or Clr.

Related Experiment Videos

Main Results:

  • The F(ab)2 fragment is expected to react only with the generated active site of Cls.
  • This specific inhibition is not anticipated to activate the complement system.
  • Suppression of Cls-mediated vascular permeability and generation of anaphylatoxins and chemotactic factors is predicted.

Conclusions:

  • Targeted inhibition of Cls active sites with F(ab)2 fragments offers a potential therapeutic strategy for CP-mediated immunological diseases.
  • This approach aims to prevent tissue destruction and reduce disease activity.
  • Further validation in experimental models is recommended.